Your session is about to expire
← Back to Search
Cardiovascular Risk Assessment for Rheumatoid Arthritis (CARE RA Trial)
N/A
Waitlist Available
Led By Iris Navarro-Milan, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age between 40 and 75 years (inclusive)
Be older than 18 years old
Must not have
Do not have rheumatoid arthritis
Younger than age 40 or older than age 75
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months post-intervention
Summary
This trial will develop an intervention to improve lipid screening and management in RA patients in order to decrease the risk for heart attacks and strokes.
Who is the study for?
This trial is for US residents aged 40-75 with Rheumatoid Arthritis who haven't had a cholesterol test in the past 2 years or discussed results with a doctor. Participants must speak English, have a phone and internet access, and be willing to work with a peer coach.
What is being tested?
The study tests an intervention aimed at improving cholesterol screening and management in RA patients. It involves patient education and decision support programs to help reduce heart attack and stroke risk by managing high cholesterol.
What are the potential side effects?
Since this trial focuses on cardiovascular risk assessment rather than medication, it does not directly involve drug-related side effects. However, any new interventions may cause stress or anxiety related to health awareness.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 40 and 75 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have rheumatoid arthritis.
Select...
I am under 40 or over 75 years old.
Select...
I have a history of heart disease.
Select...
I am currently taking a statin medication.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months post-intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months post-intervention
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of subjects screened for hyperlipidemia
Number of subjects who initiated a statin
Secondary study objectives
General Self-Efficacy Scale (GSF) score
Medication Understanding and Use Self-Efficacy Scale (MUSE) score
Patient Activation Measure (PAM) score - 13 item
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Peer coach guided online learning programExperimental Treatment1 Intervention
Group II: Self-administered online learning programPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
1,091 Previous Clinical Trials
1,154,666 Total Patients Enrolled
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH
498 Previous Clinical Trials
1,089,507 Total Patients Enrolled
45 Trials studying Rheumatoid Arthritis
560,929 Patients Enrolled for Rheumatoid Arthritis
Iris Navarro-Milan, MDPrincipal InvestigatorWeill Medical College of Cornell University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have rheumatoid arthritis.I am under 40 or over 75 years old.You haven't had a cholesterol test or discussed the results with a doctor in the past 2 years.I have a history of heart disease.You have rheumatoid arthritis.I am between 40 and 75 years old.I am currently taking a statin medication.
Research Study Groups:
This trial has the following groups:- Group 1: Peer coach guided online learning program
- Group 2: Self-administered online learning program
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.